Company profile
TRAWS PHARMA, INC.
NASDAQ:TRAWBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NARAZACICLIB | phase1_2 | — | 2 | unknown |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (35)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06757738 | phase1 | completed | 2024-08-13 | 2025-01-16 | Traws Pharma, Inc. | A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers |
| NCT02562443 | phase3 | terminated | 2015-12-02 | 2020-07-26 | Traws Pharma, Inc. | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA |
| NCT01125891 | phase1 | completed | 2009-01-01 | 2011-09-01 | Traws Pharma, Inc. | Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors |
| NCT02168725 | phase1 | terminated | 2014-06-01 | 2015-12-01 | Traws Pharma, Inc. | Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors |
| NCT07157007 | phase2 | recruiting | 2025-09-16 | 2026-02-01 | Traws Pharma, Inc. | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 |
FDA applications (0)
No records yet.